3Biotech

What 3Biotech does

3Biotech is a privately held, founder-led drug development services firm headquartered in Paris, France, providing integrated Chemistry, Manufacturing and Controls (CMC) strategy, translational research, lead optimisation and global regulatory affairs support to emerging biotech companies. Founded in 2014 by Olivier Favre-Bulle — a former CEO of Novo Nordisk Engineering France and Covance France with a PhD in biotechnology and an MBA — the firm operates with a small, remote international team across Europe and increasingly North America, deliberately positioning itself as an 'accelerator, not a consultancy firm' that embeds dedicated project teams within client organisations.

The firm's core offering rests on a three-pillar methodology (Safety, Efficacy, Manufacturability) grounded in ICH Q8–Q12 Quality-by-Design frameworks, FMEA-based risk assessment, and parallelised process development aimed at compressing time to first-in-human. Methodological capabilities span small molecules, mAbs, bispecifics, antibody-drug conjugates, cell and gene therapies, mRNA-LNP, vaccines and peptides, supported by an established global CDMO network used as an execution layer rather than a revenue channel. The flagship documented outcome is a 15-month DNA-to-Drug-Product delivery for Domain Therapeutics' DT-7012 anti-CCR8 monoclonal antibody in 2025, alongside multiple 2025 FIH deliveries across ADCs, bispecifics, mRNA-LNP and autologous cell therapy programmes.

Commercially, 3Biotech operates on a professional services / managed services model with quote-based, multi-year engagements and no publicly disclosed pricing. The customer base is diversified across early-stage and emerging European biotech startups (primary), Big Pharma acquirers conducting CMC due diligence, and biotech/health investment funds (pre-seed through Series C) engaged for milestone validation and risk assessment. 2024 operational metrics — 92 projects, 16 molecules in clinical phases and 97% customer satisfaction on execution — and ecosystem affiliations with Bpifrance (Cercle des experts), BioWin, Charleroi BioPark and Cartelis indicate a small but scaling specialist services franchise rather than a transactional consultancy.

Name

3Biotech

Legal name

3BIOTECH (Limited Company with a capital of 5,000 euros; Corporate Registry: RCS Paris 530 859 170; SIRET: 53095917000024; APE code: 7490B)

Website

https://3biotech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

3Biotech is a Paris-based, founder-led drug development services firm providing integrated CMC strategy, translational research and global regulatory affairs to European and US biotech startups, pharma acquirers and biotech investors via embedded project teams.

Ownership category

akta.pro rank

Product category

Pharmaceutical CMC Consulting Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• CMC drug development
• Pharmaceutical regulatory consulting
• Biologics manufacturing strategy
• Clinical supply chain
• Drug development consulting

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Professional services — CMC strategy and drug development consulting: Fee-for-service consulting revenue from providing CMC strategy, translational research, lead optimisation, regulatory strategy and global project management services to biotech clients. Limited Company with capital 5000 euros, privately owned and independent. Engagement models include long-term programmes and dedicated project teams ('a dedicated team is set up for each project').
2. Managed services — embedded CMC and project management teams: Long-term, team-based engagements where 3Biotech acts as an extension of the client's team, providing junior and senior CMC project managers, preclinical project managers and project managers for drug development — often delivered 100% remote across Europe and the USA with travel to client sites and CDMOs.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

3Biotech delivers CMC (Chemistry, Manufacturing, and Controls) strategy, translational research, lead optimisation, regulatory affairs and global project management services for biotech startups and pharmaceutical companies developing small molecules, monoclonal antibodies, bispecifics, ADCs, cell and gene therapies, vaccines, mRNA-LNP products and peptides. The firm operates as an "accelerator, not a consultancy firm," embedding dedicated project teams into client organisations from candidate selection through clinical proof of concept, supported by a global network of top-tier CDMOs. It serves biotech startups across Europe (with growing US cross-border work) and biotech/healthcare investment funds performing CMC due diligence.

Differentiator

Problem solved

Functional benefit

Products and services

• Lead Optimisation & Selection Refinement of drug candidates — small molecules and biologics — to improve efficacy, safety and manufacturability before clinical development. For small molecules this covers structure-activity relationship (SAR) studies and ADME-Tox profiling; for biologics it covers protein engineering, immunogenicity assessment, expression-system refinement and stability evaluation, supported by preclinical assessments.
• Translational Research Bridging preclinical discoveries to human trials via dose selection, biomarker identification and first-in-human study design, including integrated PK/PD, PBPK, TMDD, humanized model and organ-on-a-chip work and in silico epitope mapping for immunogenicity risk assessment.
• CMC (Chemistry, Manufacturing and Controls) Development Development of drug substances and products including formulation, process optimisation, analytical testing, and ensuring regulatory compliance — covering physical and chemical characteristics of drug products, quality and consistency throughout manufacturing, and QbD/DoE-aligned PPQ and CPV methodology.
• CMC Strategy End-to-end CMC strategy built on 3Biotech's three pillars (Safety, Efficacy, Manufacturability), positioning CMC as the 'first crash test' that challenges biotechs' development plans and supporting modality-agnostic coverage across small molecules, mAbs, bispecifics, ADCs, cell & gene therapies, vaccines, mRNA-LNP and peptides.
• Regulatory Strategy & Global Submissions Cross-region regulatory strategy and global project management covering IND/IMPD preparation, BLA, NDA, MAA and J-NDA submissions, and submissions / interactions with FDA, EMA, MHRA, NMPA, PMDA, ANVISA and TGA — including AI-assisted document review combined with senior scientific oversight to mitigate risks highlighted by the FDA's 2026 warning letter on inappropriate AI use.
• Continued Process Verification (CPV) Ongoing monitoring of a manufacturing process to ensure it consistently produces products with the desired quality attributes throughout the commercial lifecycle, aligned with ICH Q8-Q11 QbD principles.
• Embedded CMC & Project Management Teams (Managed Services) Long-term, team-based engagements placing junior and senior CMC project managers, preclinical project managers and drug development project managers into client teams (CDI permanent or freelance, 100% remote with travel to client sites and CDMOs across Europe and the USA).

Quantifiable outcome

• 97% customer satisfaction on execution (2024)
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered flagship, minor and core.

• Domain TherapeuticsflagshipStrategic or Co-development Partner · 1 January 2025Flagship case-study client: 3Biotech supported Domain Therapeutics with DT-7012, a novel Treg-depleting anti-CCR8 monoclonal antibody, achieving first-in-human in just 15 months from DNA sequence to Drug Product release. Includes rapid GMP readiness, targeted CDMO selection, seamless process development through fill-finish, and risk-conscious milestone-aligned planning.
• CartelisminorStrategic or Co-development Partner · 1 January 20243Biotech announced a collaboration with Cartelis, a data and CRM operational consulting firm, to explore innovative ways to (per the post title) — likely joint analytics/CRM-driven client engagement initiatives for biotech clients. No detailed commercial terms disclosed.
• BioWinminorStrategic or Co-development Partner · 1 January 20243Biotech joined BioWin, Wallonia's (Belgium) biotech research and innovation cluster, gaining access to the regional life-sciences ecosystem and member network. Provides local visibility and potential client/partner pipeline in Belgium.
• Charleroi BioParkminorStrategic or Co-development Partner · 1 January 2024Collaboration between Dominique Demonte, Head of the Brussels South Charleroi BioPark (Belgium), and Catherine Muller, Executive VP at 3Biotech — covering ecosystem engagement and visibility within the Wallonia biotech community.
• CIS BIOPHARMA (spinoff from CIS Pharma)minorStrategic or Co-development Partner · 1 January 2024CIS BIOPHARMA is the Basel-based 2023 oncology spinoff from CIS Pharma; CEO Christoph Schäfer featured in a 3Biotech blog interview — signals an ecosystem/visibility relationship with the oncology startup.
• Bpifrance (Cercle des experts)coreOthers · 1 January 2024Olivier Favre-Bulle is a member of the 'Cercle des experts Bpifrance' and is involved in the assessment of biotech projects applying to the #France2030 calls for projects. Provides access to French biotech deal flow, credibility with French biotech ecosystem, and recognition via the BIG (Bpifrance Innovation Generation) conference.
• SanoficoreOthersQuote from Olivier Bogillot, President Sanofi, featured on the Approach page citing the Bpifrance Health-Tech 2021 plan: 'Disruptive science is the basis of any innovative company. But impeccable CMC operations and regulatory records are also key assets for success.' Relationship appears as endorsement/reference rather than commercial partnership.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Others

• Veeva Systems: Cloud-based regulatory and quality software provider used by CMC teams; not a direct competitor but an enabling/adjacent technology layer for IND/IMPD workflow automation referenced in 3Biotech's AI-assisted review approach.

Broad incumbents

• IQVIA: Global life sciences services company with regulatory, CMC and clinical consulting capabilities; serves biotech and large pharma with a much broader and bundled offering.
• Lonza: Global CDMO with biologics, mRNA and cell therapy manufacturing scale; broadly comparable in modality coverage and regulatory expertise but at vastly different scale.
• Catalent: Major CDMO with biologics, cell therapy and oral dose capabilities; partner network to 3Biotech's CDMO ecosystem but competes for end-to-end CMC programmes.
• Charles River Laboratories: Global CRO/CDMO offering end-to-end CMC, biologics manufacturing and regulatory services; competes for larger biotech programmes but does not match 3Biotech's boutique, accelerator-style engagement model.

Direct peers

• PharmaLex (Cencora): Specialised regulatory and CMC consulting firm serving biotech and pharma across development phases; recently acquired by Cencora. Closest direct competitor in CMC strategy, regulatory affairs and global submission support for emerging biotechs.
• Dark Horse Consulting: Boutique CMC and manufacturing consultancy focused on cell and gene therapy, biologics and complex modalities. Comparable in operating model (senior-led, embedded teams) and modality overlap (CGT, biologics).
• Biopharma Excellence: European CMC and regulatory consultancy serving emerging biotech; small senior team with comparable focus on biologics CMC and global submission strategy.
• Voisin Consulting Life Sciences: European-based life sciences consultancy offering CMC, regulatory and clinical strategy services to biotech startups and mid-size pharma. Directly comparable in size, scope and European biotech client base.
• Pharmatech Associates (part of McKinsey): CMC and GMP compliance consultancy serving biotech and pharma. Comparable CMC execution, validation and regulatory services portfolio, particularly for process performance qualification and continued process verification.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/2019893
• Xx.com/3biotech
• Facebookfacebook.com/3biotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3Biotech